

Primary Biliary Cholangitis Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/PE8722000872EN.html>

Date: March 2022

Pages: 61

Price: US\$ 3,250.00 (Single User License)

ID: PE8722000872EN

Abstracts

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.

This report contains market size and forecasts of Primary Biliary Cholangitis Therapeutics in Global, including the following market information:

Global Primary Biliary Cholangitis Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Primary Biliary Cholangitis Therapeutics market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

OCALIVA Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Primary Biliary Cholangitis Therapeutics include Abbott Laboratories, Allergan Plc, Eli Lilly and Co., Intercept Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Biliary Cholangitis

Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Primary Biliary Cholangitis Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, by Type, 2021 (%)

OCALIVA

Ursodiol

Others

Global Primary Biliary Cholangitis Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospital

Private Clinic

Other

Global Primary Biliary Cholangitis Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Primary Biliary Cholangitis Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Primary Biliary Cholangitis Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Primary Biliary Cholangitis Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Abbott Laboratories

Allergan Plc

Eli Lilly and Co.

Intercept Pharmaceuticals Inc.

Takeda Pharmaceutical Co. Ltd.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Primary Biliary Cholangitis Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Primary Biliary Cholangitis Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL PRIMARY BILIARY CHOLANGITIS THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Primary Biliary Cholangitis Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Primary Biliary Cholangitis Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Primary Biliary Cholangitis Therapeutics Players in Global Market
- 3.2 Top Global Primary Biliary Cholangitis Therapeutics Companies Ranked by Revenue
- 3.3 Global Primary Biliary Cholangitis Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Primary Biliary Cholangitis Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Primary Biliary Cholangitis Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Players in Global Market
 - 3.6.1 List of Global Tier 1 Primary Biliary Cholangitis Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Primary Biliary Cholangitis Therapeutics Market Size Markets, 2021 & 2028

4.1.2 OCALIVA

4.1.3 Ursodiol

4.1.4 Others

4.2 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Primary Biliary Cholangitis Therapeutics Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Private Clinic

5.1.4 Other

5.2 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Primary Biliary Cholangitis Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028

6.3.2 US Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.3.3 Canada Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.3.4 Mexico Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028

6.4.2 Germany Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.3 France Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.4 U.K. Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.5 Italy Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.6 Russia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.4.8 Benelux Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028

6.5.2 China Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.5.3 Japan Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.5.4 South Korea Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.5.6 India Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028

6.6.2 Brazil Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.6.3 Argentina Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028

6.7.2 Turkey Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

- 6.7.3 Israel Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
- 6.7.4 Saudi Arabia Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028
- 6.7.5 UAE Primary Biliary Cholangitis Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Abbott Laboratories

- 7.1.1 Abbott Laboratories Corporate Summary
- 7.1.2 Abbott Laboratories Business Overview
- 7.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Major Product Offerings
- 7.1.4 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
- 7.1.5 Abbott Laboratories Key News

7.2 Allergan Plc

- 7.2.1 Allergan Plc Corporate Summary
- 7.2.2 Allergan Plc Business Overview
- 7.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Major Product Offerings
- 7.2.4 Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
- 7.2.5 Allergan Plc Key News

7.3 Eli Lilly and Co.

- 7.3.1 Eli Lilly and Co. Corporate Summary
- 7.3.2 Eli Lilly and Co. Business Overview
- 7.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Major Product Offerings
- 7.3.4 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
- 7.3.5 Eli Lilly and Co. Key News

7.4 Intercept Pharmaceuticals Inc.

- 7.4.1 Intercept Pharmaceuticals Inc. Corporate Summary
- 7.4.2 Intercept Pharmaceuticals Inc. Business Overview
- 7.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Major Product Offerings
- 7.4.4 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)
- 7.4.5 Intercept Pharmaceuticals Inc. Key News

7.5 Takeda Pharmaceutical Co. Ltd.

- 7.5.1 Takeda Pharmaceutical Co. Ltd. Corporate Summary
- 7.5.2 Takeda Pharmaceutical Co. Ltd. Business Overview

7.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Major Product Offerings

7.5.4 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Revenue in Global Market (2017-2022)

7.5.5 Takeda Pharmaceutical Co. Ltd. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Primary Biliary Cholangitis Therapeutics Market Opportunities & Trends in Global Market

Table 2. Primary Biliary Cholangitis Therapeutics Market Drivers in Global Market

Table 3. Primary Biliary Cholangitis Therapeutics Market Restraints in Global Market

Table 4. Key Players of Primary Biliary Cholangitis Therapeutics in Global Market

Table 5. Top Primary Biliary Cholangitis Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Primary Biliary Cholangitis Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Primary Biliary Cholangitis Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Primary Biliary Cholangitis Therapeutics Product Type

Table 9. List of Global Tier 1 Primary Biliary Cholangitis Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Primary Biliary Cholangitis Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Primary Biliary Cholangitis Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Primary Biliary Cholangitis Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Primary Biliary Cholangitis Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Primary Biliary Cholangitis Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Primary Biliary Cholangitis Therapeutics

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Primary Biliary Cholangitis Therapeutics

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. Abbott Laboratories Corporate Summary

Table 31. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product Offerings

Table 32. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Allergan Plc Corporate Summary

Table 34. Allergan Plc Primary Biliary Cholangitis Therapeutics Product Offerings

Table 35. Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Eli Lilly and Co. Corporate Summary

Table 37. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product Offerings

Table 38. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Intercept Pharmaceuticals Inc. Corporate Summary

Table 40. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product Offerings

Table 41. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Takeda Pharmaceutical Co. Ltd. Corporate Summary

Table 43. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics

Product Offerings

Table 44. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics
Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Primary Biliary Cholangitis Therapeutics Segment by Type in 2021
- Figure 2. Primary Biliary Cholangitis Therapeutics Segment by Application in 2021
- Figure 3. Global Primary Biliary Cholangitis Therapeutics Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Primary Biliary Cholangitis Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Primary Biliary Cholangitis Therapeutics Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Primary Biliary Cholangitis Therapeutics Revenue in 2021
- Figure 8. By Type - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
- Figure 12. US Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028
- Figure 16. Germany Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Primary Biliary Cholangitis Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Primary Biliary Cholangitis Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Primary Biliary Cholangitis Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/PE8722000872EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE8722000872EN.html>